IHS Chemical Week

Regions :: North America :: U.S.

AMRI completes acquisition of OsoBio

7:48 AM MDT | July 2, 2014 | Deepti Ramesh

Albany Molecular Research Inc. (AMRI; Albany, NY) says that it has completed the previously announced acquisition of Oso Biopharmaceuticals Manufacturing (OsoBio; Albuquerque, NM). Total consideration paid was $110 million, which AMRI financed with cash on hand. OsoBio is a contract manufacturer of highly complex injectable drug products, including sterile liquid, suspension, and lyophilized formulations. OsoBio's forecast full-year 2014 revenue is $58–60 million, with adjusted Ebitda of $9–10 million, AMRI says. OsoBio’s expertise in...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa